Drug consumption.
At baseline, 10 participants in the placebo group and 12 participants in the dulaglutide group reported consuming drugs (i.e., drugs such as cannabis, benzodiazepines, opioids, psychostimulants, or others), of which 4 in the placebo and 2 in the dulaglutide group quit. Four participants started consuming drugs in each treatment group during the study. There was no evidence to support the hypothesis that the intake of GLP-1 agonists leads to changes in the consumption of drugs (